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Abstract
Introduction: The Department of Veterans Affairs (VA) is the largest provider of HIV care in the United States. Changes in
healthcare delivery became necessary with the COVID-19 pandemic. We compared HIV healthcare delivery during the first
year of the COVID-19 pandemic to a prior similar calendar period.
Methods: We included 27,674 people with HIV (PWH) enrolled in the Veterans Aging Cohort Study prior to 1 March 2019,
with ≥1 healthcare encounter from 1 March 2019 to 29 February 2020 (2019) and/or 1 March 2020 to 28 February 2021
(2020). We counted monthly general medicine/infectious disease (GM/ID) clinic visits and HIV-1 RNA viral load (VL) tests.
We determined the percentage with ≥1 clinic visit (in-person vs. telephone/video [virtual]) and ≥1 VL test (detectable vs.
suppressed) for 2019 and 2020. Using pharmacy records, we summarized antiretroviral (ARV) medication refill length (<90
vs. ≥90 days) and monthly ARV coverage.
Results: Most patients had ≥1 GM/ID visit in 2019 (96%) and 2020 (95%). For 2019, 27% of visits were virtual compared
to 64% in 2020. In 2019, 82% had VL measured compared to 74% in 2020. Of those with VL measured, 92% and 91% had
suppressed VL in 2019 and 2020. ARV refills for ≥90 days increased from 39% in 2019 to 51% in 2020. ARV coverage was
similar for all months of 2019 and 2020 ranging from 76% to 80% except for March 2019 (72%). Women were less likely
than men to be on ARVs or to have a VL test in both years.
Conclusions: During the COVID-19 pandemic, the VA increased the use of virtual visits and longer ARV refills, while maintain-
ing a high percentage of patients with suppressed VL among those with VL measured. Despite decreased in-person services
during the pandemic, access to ARVs was not disrupted. More follow-up time is needed to determine whether overall health
was impacted by the use of differentiated service delivery and to evaluate whether a long-term shift to increased virtual
healthcare could be beneficial, particularly for PWH in rural areas or with transportation barriers. Programmes to increase
ARV use and VL testing for women are needed.
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1 INTRODUCT ION
The United States (US) Department of Veterans Affairs (VA)
provides healthcare at no or low cost to eligible veterans
and is delivered mainly through VA clinics and facilities.
The VA benefits from one of the most highly developed
health information systems in the world [1] and is one
of the first US healthcare systems to create extensive
virtual healthcare infrastructure including telephone and
video visits (henceforth referred to as “virtual”) [2,3]. With
the emergence of the COVID-19 pandemic, changes in
healthcare delivery became immediately necessary [4,5],
and the VA responded quickly by expanding virtual care
[2,6–10]. On 19 March 2020, the VA issued guidance for
“Alternative Telehealth Communication Technologies During
COVID19 National Emergency” [11]. This guidance outlined
the preferred modes of communication including VA Video
Connect and government-furnished phones, and also allowed
for the use of alternative technologies to “augment clin-
ical activities related to providing care to patients” during
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the COVID-19 pandemic [11]. By June 2020, 58% of VA visits
were virtual compared to 14% prior to March 2020 [12].
The VA is the largest provider of HIV care in the United
States [1,13]. People with HIV (PWH) need consistent HIV
healthcare engagement to maintain antiretroviral (ARV) med-
ication adherence and HIV-1 plasma RNA viral load (VL) sup-
pression [14–16]. Substance use screening is also an impor-
tant component of HIV care [17]. Since 2015, the World
Health Organization has promoted “differentiated service
delivery” for PWH to simplify access to care and to reduce
time spent in healthcare facilities [18]. One study reported
that 5% of PWH at three VA sites used telehealth during
the 3–4 years prior to the COVID-19 pandemic [19]. The
pre-pandemic criteria for virtual visits prioritized patients who
were virologically suppressed but had transportation or clinic
distance challenges.
During in-person visits, patients are typically screened by
support staff annually about health related items including
alcohol and tobacco use [20] prior to seeing the clinician. In
contrast, during virtual visits clinicians are expected to admin-
ister these screenings in addition to adjusting to the use of
technology and any corresponding trouble-shooting issues for
themselves or patients [2]. For those who utilize alcohol and
tobacco use data collected via screenings, this transition to
increased use of virtual visits during the COVID-19 pandemic
could potentially lead to gaps in information and care.
Among women receiving HIV care within the VA, a lower
percentage had ARV coverage and suppressed VL compared
to men with HIV [21], and some studies have identified
an association between race/ethnicity and lower virtual
healthcare use [22]. Whether the impact of the COVID-19
pandemic on HIV healthcare varies by race/ethnicity and/or
gender is unknown.
Understanding how the pandemic has impacted HIV health-
care service utilization, ARV adherence and substance use
disorder screening can inform efforts to maintain continu-
ity of care for PWH and other chronic health conditions
using differentiated service delivery. More specifically, exam-
ining the impact of healthcare changes for PWH may provide
broader insights into the implications of virtual care models
for other chronic diseases as well as for maximizing health-
care resources and/or helping overcome barriers to care such
as distance to clinic and/or lack of mobility or transportation
[5]. Our main goals were to compare among PWH during and
prior to the COVID-19 pandemic: (1) HIV healthcare delivery
and (2) frequency of alcohol and tobacco use screening. Sec-
ondary aims included (1) comparing HIV healthcare delivery
by race/ethnicity and gender and (2) evaluating diagnoses for
alcohol use disorder (AUD) and tobacco use/smoking during
and prior to the pandemic.
2 METHODS
2.1 Data source – Veterans Aging Cohort Study
The Veterans Aging Cohort Study (VACS) is a national cohort
of 60,055 PWH and 125,122 age-matched, race/ethnicity-
matched, sex-matched and clinical site-matched people with-
out HIV who were identified in the US VA electronic health
record in the fiscal years 1997–2020 using a modified exist-
ing algorithm [1]. Data were extracted from the VA Corporate
Data Warehouse, a national repository that incorporates
data from clinical and administrative systems into a data
warehouse structure [23]. This study was approved by the
Institutional Review Boards of the VA Connecticut Healthcare
System and Yale University School of Medicine and has been
granted a waiver of informed consent.
Within VACS, we identified PWH who entered care prior
to 1 March 2019 with evidence of at least one outpatient
VA healthcare encounter of any type including, but not limited
to, general medicine (GM), infectious disease (ID), emergency
care, mental health, pharmacy and laboratory from 1 March
2019 to 28 February 2021, and were alive at the end of the
study period (28 February 2021). Due to the emerging body
of evidence regarding health needs for persons infected with
SARS-CoV-2, we excluded 1524 PWH who had an indication
of a positive SARS-CoV-2 PCR laboratory test up to 28 Febru-
ary 2021. The analytic sample included 27,674 PWH.
2.2 Variable definitions
Age, race/ethnicity and sex were determined as of 1 March
2019. We identified GM/ID clinic visits related to HIV pri-
mary care (VA clinic stop codes: 27, 170, 172, 301, 310,
318, 319, 323, 324, 338, 348, 349, 350, 311). Virtual (video
or telephone) visits were determined based on methodology
adapted from Ferguson and colleagues [12]. HIV-1 RNA VL
was categorized as suppressed (≤50 copies/ml), detectable
(>50 copies/ml) and not measured. ARV pharmacy fill/refill
length was categorized as <60, 60–89 and ≥90 days.
We identified PWH who were screened with the Alco-
hol Use Disorder Identification Test-Consumption (AUDIT-C)
and for tobacco use history via the clinical reminder sys-
tem [19,20]. Unhealthy alcohol use was based on AUDIT-C
≥ 4 for men or ≥3 for women [24]. Tobacco use was iden-
tified as current, past or never based on responses to two
clinical reminder questions: “Do you smoke cigarettes or use
tobacco every day, some days, or not at all”?; and those who
responded “not at all” were asked about former or never
use. For those with multiple responses per year, we used
the response representing the highest level of use. Addition-
ally, we identified for each year those with at least one out-
patient International Classification of Diseases, Tenth Revi-
sion, Clinical Modification (ICD-10) diagnosis code for AUD
using codes F10.1x, F10.2x [25] or tobacco use/smoking using
codes Z72.0x, F17.21, Z87.891.
2.3 Analyses
For each month of 1 March 2019 to 29 February 2020
(2019) and 1 March 2020 to 28 February 2021 (2020),
we summarized counts of GM/ID clinic visits (in-person vs.
virtual), HIV-1 RNA VL tests, ARV prescriptions by length,
AUDIT-C administered and tobacco use responses collected.
We also calculated the percentage of patients with ARV cov-
erage for each month based on prescription fill dates, days,
supply and an additional half day supply was added to approx-
imate lag time and overlap of fills.
For each period in 2019 and 2020 we calculated the per-
centage of individuals with ≥1 clinical encounter (by type),
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Figure 1. Healthcare services among 27,674 PWH in 2019 and 2020
ARV, antiretroviral therapy; VL, viral load; 2019, 1 March 2019 to 28 February 2020; 2020, 1 March 2020 to 29 February 2021.
≥1 HIV-1 RNA VL test (by detectable/suppressed) and
any ARV use. We determined whether having ≥1 clinical
encounter, ≥1 HIV-1 RNA VL test, or any ARV use varied by
race/ethnicity and gender. Additionally, we calculated the per-
centage screened for AUDIT-C and tobacco use along with
corresponding responses for each year. Lastly, we calculated
the percentage with an ICD-10 diagnosis for alcohol use dis-
order (AUD) or smoking/tobacco use for each year.
3 RESULTS
Of the 27,674 PWH enrolled in VACS prior to March
2019 and with at least one healthcare encounter in 2019
or 2020, the median age was 59 years (range = 23–
97), 96% were men, 45% non-Hispanic Black (Black), 35%
non-Hispanic White (White), 8% Hispanic, 3% other (Amer-
ican Indian, Asian, Pacific Islander or mixed race) and 9%
unknown (Table 1). Almost everyone had at least one health-
care encounter of any type in 2019 (99%; 27,493) and 2020
(98%; 27,107). For all months except May, there were more
visits in 2020 than in 2019 (Figure 1a). The transition to a
higher percentage of virtual visits started in March 2020 and
continued throughout February 2021 (Figure 1a). In 2019,
27% of visits were virtual compared to 64% in 2020. Of the
virtual visits, 99% and 92% were by telephone (vs. video)
in 2019 and 2020, respectively. Considering GM/ID clinics
specifically, almost all patients had at least one virtual or in-
person GM/ID clinic visit in 2019 (96%) and 2020 (95%)
and this was similar for those of Black, White and Hispanic
race/ethnicity and for men and women. For those of other
or unknown race/ethnicity, the percentage with at least one
GM/ID encounter in 2020 was slightly lower – 93% and 91%,
respectively (Table 2). Compared to men, women were less
likely to have in-person visits (91% vs. 95% in 2019 and 77%
vs. 80% in 2020) and more likely to have virtual visits (62%
vs. 57% in 2019 and 92% vs. 89% in 2020). Having any
GM/ID clinic visits was similar by gender in both years rang-
ing from 94% to 96% (Table 2).
There were fewer HIV-1 RNA VL tests in 2020, particu-
larly in the months of April and May (Figure 1b). In 2019,
82% had VL measured compared to 74% in 2020. Of those
with VL measured, 92% and 91% had suppressed VL in 2019
and 2020, respectively. The percentage of PWH with VL mea-
sured in 2019 was similar among those of Black, White and
other race/ethnicity (82%–83%), and slightly higher among
Hispanic PWH (86%) and lower among those with unknown
race/ethnicity (70%). The pattern was similar for 2020; the
percentage with VL in 2020 was similar among those of Black,
White and other race/ethnicity (73%–75%), and slightly higher
among Hispanic PWH (78%) and lower among those with
unknown race/ethnicity (63%) (Table 2). Compared to men,
women were less likely to have VL measured in 2019 (73%
vs. 82%) and 2020 (67% vs. 74%) (Table 2).
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Table 1. Characteristics of people with HIV in the Veterans
Aging Cohort Study (n = 27,674)
Characteristics











HIV healthcare (%) 2019 2020
GM/ID visit
Any 96 95
In person 95 80
Virtual 57 89
HIV-1 RNA VL test detectable 6 7
HIV-1 RNA VL test suppressed 76 67
No test 18 26
On ARVS 85 84
Alcohol use (%)
AUDIT-C – clinical reminder
0 (no use) 35 29
1–3/1–4 (some use) 30 23
>3/>4 (unhealthy use) 10 7
Not asked 25 40






Not asked 26 40
Diagnosis 20 18
Abbreviations: ARV, antiretroviral therapy; AUDIT-C, Alcohol
use disorder identification test-consumption; GM/ID, general
medicine/infectious diseases; SD, standard deviation; VL, HIV-1 RNA
viral load; 2019, 1 March 2019 to 28 February 2020; 2020, 1
March 2020 to 29 February 2021.
There were fewer ARV refills in all months of 2020 com-
pared to 2019 except for in March. However, the percent-
age with a refill of ≥90 days was higher for all months in
2020 (Figure 1c). Overall, in 2020 51% of refills were for
≥90 days compared to 39% in 2019. Even though there
was a lower number of refills in 2020 compared to 2019,
because average prescription length was longer, ARV coverage
was similar for all months of 2019 and 2020, ranging from
76% to 80% for all months except for March 2019 (72%)
(Figure 1d). In 2019 and 2020, 85% and 84% had any
ARV use, respectively. The percentage with ARV coverage
Figure 2. Screening for alcohol and tobacco use among 27,674
PWH in 2019 and 2020
AUDIT-C, Alcohol Use Disorder Identification Test-Consumption;
2019, 1 March 2019 to 28 February 2020; 2020, 1 March 2020
to 29 February 2021.
was similar for those of Black, White, Hispanic and other
race/ethnicity for both 2019 and 2020 (ranging from 85%
to 86%). For those of unknown race/ethnicity, only 75% had
any ARV use in both years (Table 2). Women were less
likely than men to have ARV coverage in 2019 (75% vs.
85%) and 2020 (74% vs. 85%). There was little change in
ARV coverage for either gender during the study period
(Table 2).
AUDIT-C was collected less frequently for all months in
2020 compared to 2019, but only slightly less frequently in
November and December (Figure 2). The AUDIT-C was com-
pleted for 75% of PWH in 2019 and 60% in 2020 (Table 1). In
2019, 10% had an AUDIT-C score indicating unhealthy alco-
hol use compared to 7% in 2020. In 2019, of those who only
had a virtual visit, 25% had AUDIT-C responses compared to
73% of those with only an in-person visit. However, in 2020
the percentage with AUDIT-C responses was similar for those
with only virtual compared to only in-person visits (44% vs.
46%). In 2019, 10% had an AUD diagnosis compared to 8%
in 2020.
Tobacco use was collected less frequently for all months in
2020 compared to 2019 (Figure 2). The tobacco use items
collected through the clinical reminder system were com-
pleted for 74% in 2019 and 60% in 2020. In 2019, 27%
reported current tobacco use and 23% past tobacco use; in
2020, 20% reported current tobacco use and 19% reported
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Table 2. HIV healthcare by race/ethnicity and gender in 2019 and 2020 (n = 27,674)
GM/ID visit VL On
Any (%) In person (%) Virtual (%) Measured (%) ARVs (%)
Race/ethnicity N 2019 2020 2019 2020 2019 2020 2019 2020 2019 2020
Black 12,577 96 95 96 81 56 90 83 75 85 85
White 9759 96 95 96 81 59 90 82 75 86 85
Hispanic 2167 96 95 95 82 60 91 86 78 86 86
Other 713 96 93 94 78 60 87 83 73 86 85
Unknown 2485 93 91 91 71 53 84 70 63 75 75
Gender
Men 26,661 96 95 95 80 57 89 82 74 85 85
Women 1013 94 95 91 77 62 92 73 67 75 74
Abbreviations: ARV, antiretroviral therapy; GM/ID, general medicine/infectious diseases; VL, HIV-1 RNA viral load; 2019, 1 March 2019 to 28
February 2020; 2020, 1 March 2020 to 29 February 2021.
past tobacco use (Table 1). In 2019, of those with only virtual
visits, 21% had any tobacco use responses compared to 72%
of those with only an in-person visit. However, in 2020 the
percentage with tobacco use information was more similar for
those with only virtual compared to only in-person visits (46%
vs. 44%). In 2019, 17% had a tobacco use diagnosis compared
to 15% in 2020.
4 D ISCUSS ION
In response to the COVID-19 pandemic, the US VA ramped
up the use of virtual visits (over 90% of virtual visits were
telephone based) and increased refill length for ARVs for
PWH. Despite a lower level of in-person care and HIV-1
RNA VL tests during the pandemic, the percentage with sup-
pressed HIV-1 RNA VL remained similar (among those for
whom it was measured) and access to ARVs was maintained.
HIV healthcare before and during the pandemic was similar
for those of Black, White, Hispanic and other race/ethnicities
and for men and women. However, alcohol and tobacco use
screening occurred less frequently among PWH with the
increased use of virtual care during the pandemic.
The finding of increased virtual visits for PWH from 27%
in 2019 to 64% in 2020 is consistent with findings of other
(non-HIV specific) studies earlier in the pandemic [2,12] as
well as with VA guidance and support in the form of addi-
tional training and tablets that were provided for virtual vis-
its. Ferguson et al. reported that virtual visits increased from
14% prior to COVID-19 to 58% in June 2020; they also
noted that virtual visits were more common among those with
higher clinical or social needs [12]. During the pandemic, the
VA Central Office recommended that newly diagnosed PWH
with an opportunistic infection, low CD4 count, or serious
ARV adverse event should be seen in an expedited matter
in-person or virtually, depending on patient preference. In-
person visits in ID clinics were restricted to patients with
urgent care needs without COVID-19 symptoms, patients
presenting for same day ARV and routinely scheduled patients
who were considered high risk (e.g., active opportunistic infec-
tions, high VL and low CD4 count).
The number of VL tests was particularly low in April and
May 2020 (early in the pandemic). While routine VA lab-
oratory testing was available throughout the pandemic, but
with a transition from mostly “walk-in” phlebotomy in close
quarters to socially distanced appointments and limited to
provider-defined essential blood draws early in the pandemic.
While the number of ARV prescriptions was lower in 2020
compared to 2019, the percentage of prescriptions over 90
days was greater in 2020 compared to 2019. ARV pre-
scriptions were refilled automatically (mostly via mail service)
regardless of prior appointment attendance (encouraged but
not mandatory) or whether laboratory testing was done. The
VA has one of the most highly rated prescription mail order
services that was providing around 80% of VA outpatient
medications even before the start of the COVID-19 pandemic
[26,27]. This differentiated service delivery likely contributed
to ARV coverage being maintained throughout the pandemic.
Several studies have reported that those of Black and His-
panic race/ethnicity have been disproportionately negatively
impacted by COVID-19 with regard to testing, positivity rates
and the vaccine rollout [28–30]. In this study of PWH receiv-
ing care in the VA, we found that HIV care during and prior to
the COVID-19 pandemic was similar by race/ethnicity except
for those of unknown race/ethnicity and this is consistent with
a previous study that reported that HIV clinical management
and adherence in the VA was similar by race/ethnicity [31].
Because having unknown race/ethnicity in the VA is also asso-
ciated with having fewer VA visits, this finding is difficult to
interpret, but may suggest less engagement in VA care.
While having any type of GM/ID visit was similar during
and prior to the COVID-19 pandemic and by gender, we did
identify differences in HIV care by gender. During both time
periods, women were less likely than men to have in-person
GM/ID visits, to have VL measured and to be covered by
ARVs. This finding is consistent with a previous study of the
HIV care continuum using US VA data [21].
AUDIT-C and smoking/tobacco use screenings were admin-
istered to a substantially lower percentage of PWH during
the COVID-19 pandemic. Before the pandemic, clinical staff
usually administered the screenings during in-person visits.
It is likely that during the pandemic, in-person visits were
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more focused on urgent issues and, therefore, routine screen-
ing questionnaires may not have been administered as fre-
quently (this could be similarly true for virtual visits in 2019).
Early in the pandemic, nurses triaged and screened only in-
person visits, leaving providers to add these screenings to
their workflow. These findings indicate that providers were
able to adapt to administering the screenings during virtual
visits without the same level of support staff. This is likely
emblematic of a rapid uptake of virtual care modalities to
replace in-person visits in 2020, as opposed to ad hoc, urgent
or interim virtual assessments in 2019, which would be less
likely to include routine preventive healthcare. Alcohol and
tobacco use screening was done less frequently in 2020 dur-
ing both in-person and virtual visits and this represents an
important area for improvement.
Later in the pandemic, nurses started calling, triaging and
screening patients before virtual visits. However, the timing
and process for this change likely varied by site, may not
be reflected in these data, and warrants follow-up research.
Although providers took on the additional workload of admin-
istering the alcohol/tobacco screenings during virtual visits,
this may not be an efficient or effective use of time in the
long term. Integrating the use of support staff during virtual
visits may be a way to improve screening. While ARV cover-
age was maintained during the pandemic, the lower frequency
of substance use screening may have deleterious implications
for other preventive care measures and to overall health out-
comes in the coming months–years.
This study has some limitations. We excluded 2689 people
who died or tested positive for SARS-CoV-2 during the
study timeframe, which could have excluded PWH who were
particularly vulnerable. Compared to those excluded, the
27,674 included were slightly more likely to be women (3.7%
vs. 2.9%), younger (mean = 58.7 vs. 61.1 years) and less
likely to be of Black race (45% vs. 51%). Most of the PWH
are men so results for women may not generalize to non-
VA PWH populations. However, we believe these concerns
are addressed in the results by race/ethnicity and gender
(Table 2). The similar percentage with detectable HIV-1 RNA
VL between 2019 and 2020 should be interpreted with cau-
tion because there is a higher percentage without measured
VL in 2020 and missing VL may be associated with lower
ARV use. Additional follow-up time is needed to determine
whether those without a VL measurement in 2020 are of
similar health status as those without a VL measurement in
2019. However, it is reassuring that ARV coverage is similar
before and during the pandemic and suggests that aspects
of the differentiated service delivery during the COVID-19
pandemic may be worth continuing post-pandemic. Of note,
ARV coverage was lower for March 2019 than for any
other month, and we surmise this is because we included
those identified in VACS up to 1 March 2019 and there
are likely some PWH who were new to HIV care up to this
date.
5 CONCLUS IONS
With the emergence of the COVID-19 pandemic, the US VA
substantially increased the use of virtual (mostly telephone)
visits and longer refills (mostly by mail) for ARVs, maintain-
ing a high percentage of patients with suppressed VL among
those with VL measured. Despite a lower level of in-person
services for PWH during the pandemic, access to ARVs was
not disrupted. More observation time is needed to determine
whether the health of PWH, measured by VL suppression,
CD4 cell count, comorbidity diagnoses and other long-term
outcomes, was impacted by the differentiated service deliv-
ery and to evaluate whether a long-term shift to increased
use of virtual healthcare could be beneficial, particularly for
those in rural areas or with transportation barriers. Findings
could have long-term implications for more efficient HIV care
in general, perhaps involving longer prescription fills, greater
use of mail in prescription services, fewer in-person visits and
less frequent VL tests.
Future research should evaluate whether newly diagnosed
PWH had more challenges achieving VL suppression during
the COVID-19 pandemic. In the short term, it is reassuring
that the level of GM/ID visits and ARV use remained consis-
tent and that healthcare during this period of the US COVID-
19 pandemic was similar for PWH of Black, White, Hispanic
and other race/ethnicities. However, a concerning finding is
that ARV use and VL testing were lower for women than
men both before and during the pandemic. Further studies
are needed to evaluate the assessment of and treatment for
HIV and substance use during the COVID-19 pandemic.
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